Cardiovascular diseases (CVDs) are pointed out by the World Health Organization (WHO)
as the leading cause of death, contributing to a significant and growing global health and …

Cardiovascular Disease (CVD) is a leading cause of mortality within the United States.
Current treatments being administered to patients who suffered a myocardial infarction (MI) …

Background Living grafts produced by combining autologous heart‐resident stem/progenitor
cells and tissue engineering could provide a new therapeutic option for definitive correction …

Limited therapies exist for patients with congenital heart disease (CHD) who develop right
ventricular (RV) dysfunction. Bone marrow-derived mesenchymal stem cells (MSCs) have …

Despite advances in surgical technique and postoperative care, long-term survival of
children born with hypoplastic left heart syndrome (HLHS) remains limited, with cardiac …

Successful cell therapy requires cells to resist the hostile ischemic myocardium, be retained
to continue secreting cardioprotective growth factors/exosomes, and resist immunological …

Simple Summary Congenital heart defect (CHD) is the most common birth defect that affects
the structure of the heart from birth. A possible reason for this occurrence could be …

Dramatic evolution in medical and catheter interventions and complex surgeries to treat
children with congenital heart disease (CHD) has led to a growing number of patients with a …

Background We have previously reported the possibility of using pericytes from leftovers of
palliative surgery of congenital heart disease to engineer clinically certified prosthetic grafts …

Transplantation of human allogeneic induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs) is a new, promising treatment for severe heart failure. However …